2023 World Conference on Lung Cancer (Posters)-EP07.04. Comparison of Pathologic Outcomes Following Neoadjuvant Regimens in Resectable Locally Advanced Non-Small Cell Lung Cancer

EP07.04. Comparison of Pathologic Outcomes Following Neoadjuvant Regimens in Resectable Locally Advanced Non-Small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

This study compared the pathologic outcomes of different neoadjuvant therapy regimens in patients with resectable locally advanced non-small cell lung cancer (LA-NSCLC). The analysis included patients who underwent two cycles of platinum-based chemotherapy prior to surgery and had available pathologic complete response (pCR) data.<br /><br />The study found that both neoadjuvant chemo-immunotherapy and chemo-radiotherapy showed early signals of higher pCR rates compared to chemotherapy alone. Specifically, neoadjuvant chemo-immunotherapy had a pCR rate of 32.1%, while chemo-radiotherapy had a rate of 31.8%. In contrast, the pCR rate for chemotherapy alone was only 8.7%.<br /><br />Further analysis revealed that clinical stage and year of diagnosis were associated with the type of neoadjuvant therapy received. However, there were no significant associations between age, gender, BMI, histology, PD-L1 staining, and type of therapy.<br /><br />The authors suggest that as neoadjuvant chemo-immunotherapy becomes more commonly used, it is important to analyze its impact on pathologic response, event-free survival, overall survival, toxicity, and quality-of-life. They also recommend prospective clinical trials to evaluate the effectiveness of neoadjuvant chemo-immunotherapy and chemo-radiotherapy in patients with LA-NSCLC.<br /><br />The study utilized the Flatiron Health database, a de-identified database derived from electronic health records, to analyze the patient data. The database included 73 patients diagnosed with stage II-IIIA NSCLC between January 2019 and March 2023. The majority of patients in the database were from community oncology settings.<br /><br />In conclusion, this study suggests that neoadjuvant chemo-immunotherapy and chemo-radiotherapy may have higher rates of pCR compared to chemotherapy alone in patients with resectable LA-NSCLC. Further research is needed to evaluate the long-term outcomes and determine the optimal treatment approach for these patients.

Asset Subtitle

Nicholas Wells

Meta Tag

Speaker Nicholas Wells

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

neoadjuvant therapy

pathologic outcomes

resectable LA-NSCLC

platinum-based chemotherapy

pathologic complete response

pCR rates

chemo-immunotherapy

chemo-radiotherapy

clinical stage

prospective clinical trials